TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.

Laura Waters et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.